(Q40526147)

21 September 2017

1 reference

title

Continuous versus intermittent subcutaneous infusion of octreotide in the treatment of acromegaly (English)

1 reference

21 September 2017

Harris AG

1

1 reference

21 September 2017

Kokoris SP

series ordinal

2

1 reference

21 September 2017

Ezzat S

series ordinal

3

1 reference

21 September 2017

publication date

1 January 1995

1 reference

The Journal of Clinical Pharmacology

21 September 2017

published in

1 reference

21 September 2017

volume

35

1 reference

21 September 2017

issue

1

1 reference

21 September 2017

page(s)

59-71

1 reference

SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged action

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1995.TB04746.X

Recurrent acromegaly resulting from ectopic growth hormone gene expression by a metastatic pancreatic tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1995.TB04746.X

Clinical review 18: Are patients with acromegaly at increased risk for neoplasia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1995.TB04746.X

The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1995.TB04746.X

Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1995.TB04746.X

Comparison of the effectiveness of 2-hourly versus 8-hourly subcutaneous injections of a somatostatin analog (SMS 201-995) in the treatment of acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1995.TB04746.X

Shrinking of a growth hormone-producing pituitary tumor by continuous subcutaneous infusion of the somatostatin analog SMS 201-995.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1995.TB04746.X

A comparison of octreotide delivered by continuous subcutaneous infusion with intermittent injection in the treatment of acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1995.TB04746.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1995.TB04746.X

Treatment of resistant acromegaly with a long-acting somatostatin analogue (SMS 201-995).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1995.TB04746.X

Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1995.TB04746.X

Gallstones during octreotide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1995.TB04746.X

Changes in glucose tolerance and development of gall stones during high dose treatment with octreotide for acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1995.TB04746.X

Gastrointestinal side-effects of octreotide during long-term treatment of acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1995.TB04746.X

Gall stones and treatment with octreotide for acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1995.TB04746.X

10.1002/J.1552-4604.1995.TB04746.X

21 January 2018

Identifiers

DOI

1 reference

release_fpoe72f2unffhkhffroc3couye

21 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/fpoe72f2unffhkhffroc3couye

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference